199 related articles for article (PubMed ID: 28522279)
21. DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K; Zehentmayr F; Deutschmann H; Dagn K; Exeli AK; Kopp P; Porsch P; Maurer B; Studnicka M; Sedlmayer F
Strahlenther Onkol; 2017 Apr; 193(4):315-323. PubMed ID: 28116446
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic Body Radiotherapy for Large (> 5 cm) Non-Small-Cell Lung Cancer.
Peterson J; Niles C; Patel A; Boujaoude Z; Abouzgheib W; Goldsmith B; Asbell S; Xu Q; Khrizman P; Kubicek GJ
Clin Lung Cancer; 2017 Jul; 18(4):396-400. PubMed ID: 28040379
[TBL] [Abstract][Full Text] [Related]
23. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
[TBL] [Abstract][Full Text] [Related]
24. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Rehn Ericsson S; Johansson KA; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
Acta Oncol; 2006; 45(7):787-95. PubMed ID: 16982541
[TBL] [Abstract][Full Text] [Related]
25. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.
Xia T; Li H; Sun Q; Wang Y; Fan N; Yu Y; Li P; Chang JY
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):117-25. PubMed ID: 16765528
[TBL] [Abstract][Full Text] [Related]
26. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY
Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556
[TBL] [Abstract][Full Text] [Related]
27. Never too old: A single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer.
Videtic GMM; Woody NM; Reddy CA; Stephans KL
Pract Radiat Oncol; 2017; 7(6):e543-e549. PubMed ID: 28867545
[TBL] [Abstract][Full Text] [Related]
28. [Tolerance of hypofractionated stereotactic radiotherapy for hepatic tumours].
Le Bon M; Lapeyre M; Moreau J; Bellière-Calandry A; Pezet D; Abergel A; Bellini R; Kwiatkowski F; Verrelle P; Martin F; Benoît C
Cancer Radiother; 2019 Sep; 23(5):385-394. PubMed ID: 31300328
[TBL] [Abstract][Full Text] [Related]
29. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
31. Image-guided hypofractionated small volume radiotherapy of non-small cell lung cancer - feasibility and clinical outcome.
Janssen S; Dickgreber NJ; Koenig C; Bremer M; Werner M; Karstens JH; Welte T; Meyer A
Onkologie; 2012; 35(7-8):408-12. PubMed ID: 22846971
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients.
Nyman J; Johansson KA; Hultén U
Lung Cancer; 2006 Jan; 51(1):97-103. PubMed ID: 16213059
[TBL] [Abstract][Full Text] [Related]
33. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer.
Faria SL; Souhami L; Portelance L; Duclos M; Vuong T; Small D; Freeman CR
Radiat Oncol; 2006 Nov; 1():42. PubMed ID: 17078878
[TBL] [Abstract][Full Text] [Related]
34. Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience.
Figlia V; Mazzola R; Cuccia F; Alongi F; Mortellaro G; Cespuglio D; Cucchiara T; Iacoviello G; Valenti V; Molino M; Verderame F; Matranga D; Casto AL; Ferrera G
Radiol Med; 2018 Jun; 123(6):406-414. PubMed ID: 29455424
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
36. Radiation-induced lung toxicity predictors: Retrospective analysis of 90 patients treated with stereotactic body radiation therapy for stage I non-small-cell lung carcinoma.
Menoux I; Antoni D; Mazzara C; Labani A; Charloux A; Quoix E; Falcoz PE; Truntzer P; Noël G
Cancer Radiother; 2020 Apr; 24(2):120-127. PubMed ID: 32173269
[TBL] [Abstract][Full Text] [Related]
37. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
38. Changes in Pulmonary Function Following Image-Guided Stereotactic Lung Radiotherapy: Neither Lower Baseline Nor Post-SBRT Pulmonary Function Are Associated with Worse Overall Survival.
Stone B; Mangona VS; Johnson MD; Ye H; Grills IS
J Thorac Oncol; 2015 Dec; 10(12):1762-9. PubMed ID: 26334751
[TBL] [Abstract][Full Text] [Related]
39. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis.
Urbanic JJ; Turrisi AT; Sharma AK; Silvestri GA; Williams TE; Vanek KN; Sherman CA
J Thorac Oncol; 2006 Feb; 1(2):112-9. PubMed ID: 17409839
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic body radiotherapy for patients with non-small-cell lung cancer using RapidArc delivery and a steep dose gradient: prescription of 60% isodose line of maximum dose fitting to the planning target volume.
Tsurugai Y; Takeda A; Sanuki N; Eriguchi T; Aoki Y; Oku Y; Akiba T; Sugawara A; Kunieda E
J Radiat Res; 2019 May; 60(3):364-370. PubMed ID: 30668868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
